PRESS RELEASE 2016

• Ferring and IMAB sign licensing agreement granting IMAB exclusive rights in Asia to olamkicept for the treatment of autoimmune disease

By pulse in PRESS RELEASE 2016 on 19 December 2016

Ferring Pharmaceuticals and IMAB today announced that they have signed a licensing agreement which grants IMAB exclusive rights…

• Ferring receives EU approval for REKOVELLE® (follitropin delta)

By pulse in PRESS RELEASE 2016 on 13 December 2016

Ferring Pharmaceuticals announced today that the European Commission (EC) has granted marketing authorisation for REKOVELLE®…

• Ferring Pharmaceuticals collaborates with MetaboGen AB on development of microbiome-based treatment for intrahepatic cholestasis of pregnancy (ICP)

By pulse in PRESS RELEASE 2016 on 05 December 2016

Ferring Pharmaceuticals and MetaboGen AB today announced a multi-year research collaboration…

• Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos collaborate on nanotechnology R&D platform

By pulse in PRESS RELEASE 2016 on 30 November 2016

Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced a long-term collaboration aimed at improving…

• Ferring receives positive CHMP opinion for REKOVELLE® (follitropin delta)

By pulse in PRESS RELEASE 2016 on 17 October 2016

Ferring Pharmaceuticals announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion…

• Ferring Pharmaceuticals and North Zealand University Hospital mark first milestone in innovative IBD collaboration

By pulse in PRESS RELEASE 2016 on 31 August 2016

Ferring Pharmaceuticals and North Zealand University Hospital (Nordsjællands Hospital) yesterday formally inaugurated…

• Ferring Pharmaceuticals Acquires Exclusive Licensing Rights to Condoliase from Seikagaku Corporation

By pulse in PRESS RELEASE 2016 on 29 August 2016

Ferring Pharmaceuticals announced today that it has signed an agreement with Seikagaku Corporation granting Ferring the exclusive worldwide rights…

• Ferring announces Phase 3 data for investigational human recombinant FSH with individualised dosing regimen at the 32nd Annual Meeting of ESHRE®

By pulse in PRESS RELEASE 2016 on 04 July 2016

Data from the Phase 3 ESTHER trials (Evidence-based Stimulation Trial with Human recombinant follicle-stimulating hormone…

• Ferring Pharmaceuticals announces approval of new tailored dosing regimen in the PICOPREP® (sodium picosulfate, magnesium oxide, citric acid) label in MRP countries in Europe

By pulse in PRESS RELEASE 2016 on 27 June 2016

Ferring Pharmaceuticals has successfully finalised a Mutual…

• Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program

By pulse in PRESS RELEASE 2016 on 21 June 2016

The Ferring Innovation Grants Program, which is now open for applications, has been significantly expanded as part of Ferring’s continued commitment to investing in research and development…